Clinical Trials Logo

Filter by:
NCT ID: NCT06447766 Completed - Food Insecurity Clinical Trials

Pediatric Parental Feeding Video Education Program

Start date: September 12, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about the acceptability and feasibility of nutrition education videos among food-insecure parents and caregivers of young children (under 8 years old). Participants will: - Watch short nutrition education videos weekly for 8 weeks. - Complete demographic and nutrition behavior questionnaires at week 1 and week 8. - Participate in three motivational interview phone calls with a nutrition educator lasting 20 minutes over the course of 8 weeks.

NCT ID: NCT06447506 Not yet recruiting - Dermatitis, Atopic Clinical Trials

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

AtDvance
Start date: June 4, 2024
Phase: Phase 2
Study type: Interventional

The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).

NCT ID: NCT06447493 Recruiting - Shoulder Clinical Trials

Effects of Spencer's Technique on Shoulder Function

Start date: August 15, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to see the impact of a modified Spencer's technique on tissue stiffness, mobility, and blood flow of the shoulder joint. Spencer's technique is a well-known osteopathic manipulative treatment (OMT) that is common for treating adhesive capsulitis and is believed to help blood flow. There are studies that look at the clinical effects of the technique and/or compare it to other techniques; however, measuring the extent to which Spencer's technique, or this modified technique, improves tissue stiffness and blood flow has never been written in the literature. This study will serve as a proof of concept that this technique improves tissue stiffness, blood flow, and mobility of the shoulder join as well as the nearby areas. Using ultrasound, the investigators will measure tissue stiffness and blood flow and will analyze the mobility of the shoulder joint using a Vicon motion capture system.

NCT ID: NCT06447376 Not yet recruiting - Clinical trials for Non-Hodgkin Lymphoma

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Start date: August 1, 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to is to determine the safety, feasibility and efficacy of siltuximab prophylaxis of cytokine release syndrome and neurotoxicity occurring after epcoritamab subcutaneous administration for participants with large b-cell lymphoma (DLBCL) or follicular lymphoma (FL). Participants will receive siltuximab, prior to the infusion of epcoritamab. Epcoritamab is administered in 28 day cycles for one year. After this infusion, the physician will continue to watch participants for side effects and follow the condition for a minimum of 60 days.

NCT ID: NCT06447246 Enrolling by invitation - Childhood Obesity Clinical Trials

Respiratory Effects of Obesity in Children: Longitudinal Consequences After 6 Years of Aging

Start date: June 17, 2024
Phase:
Study type: Observational

The purpose of the study is to re-examine body composition, respiratory function, exercise tolerance, and dyspnea on exertion (DOE) in children with obesity (CWO) and children without obesity (CWOO) who were originally studied as 8-12-year-olds between 2016-2023 (i.e., originally Tanner score ≤ 3; 90 participants; 26 CWOO & 64 CWO). Additionally, the investigators will study the effects of weight loss on body composition, respiratory function, exercise tolerance, and DOE in CWO.

NCT ID: NCT06447233 Recruiting - Clinical trials for Patient Satisfaction

Patient Perspectives Medicaid Title XIX Sterilization Consent Form

Start date: April 29, 2024
Phase:
Study type: Observational

The goal of this survey and interview study is to learn about patient experience consenting for permanent contraception using the Medicaid Title XIX Sterilization Consent form. The main questions it aims to answer are: - To explore patient perspectives on and understanding of the current consenting process for obtaining permanent contraception as it relates to the Medicaid Title XIX Sterilization consent form. - To explore patient experience with the current consenting process, and thoughts regarding the ideal consenting process including how it would differ from the one currently in place, if at all. Participants will complete a 10-15 minute survey and be offered participation in an in-depth one-on-one interview.

NCT ID: NCT06447194 Not yet recruiting - Clinical trials for Degenerative Disc Disease

Effect of RECK in Posterior Spinal Fusion

Start date: April 1, 2025
Phase: Phase 1/Phase 2
Study type: Interventional

"RECK" is a combination of local anesthesia medications, used for the purpose of pain control. RECK is an acronym which stands for Ropivacaine, Epinephrine, Clonidine, and Ketorolac. The purpose of this study is to investigate the effect of RECK local injectable anesthetic in the setting of posterior spinal fusion. Our specific aims are the following. Primary aim: to investigate the effect of RECK local injectable anesthetic on postoperative VAS pain scores. Secondary aims: to investigate of effect of RECK injection on postoperative opioid consumption and hospital length of stay. Hypothesis: RECK injection will significantly decrease postoperative VAS pain score, opioid consumption, and hospital length of stay compared to placebo controls.

NCT ID: NCT06447103 Not yet recruiting - Clinical trials for Clear Cell Renal Cell Carcinoma

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial compares the safety and effectiveness of 89Zr-DFO-GmAb positron emission tomography (PET)/computed tomography (CT) compared to contrast-enhanced CT after surgery in detecting clear cell renal cell cancer that has come back (recurrent). For some patients, the risk of recurrence after surgery remains high. Conventional CT methods, such as contrast-enhanced CT, may not detect small volume or micrometastatic disease. PET/CT with radiotracers, such as 89Zr-DFO-GmAb, may improve detection of tumor cells. Girentuximab (GmAb), a monoclonal antibody, is tagged with zirconium-89, a radioactive atom (which is also known as an isotope). The zirconium-89 (89Zr) isotope is attached to girentuximab with desferrioxamine (DFO) and this combined product is called 89Zr-DFO-girentuximab. 89Zr-DFO-girentuximab attaches itself to a protein on the surface of clear cell renal cell tumor cells called CAIX. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 89Zr-DFO-GmAb. Because some cancers, including clear cell renal cell cancer, take up 89Zr-DFO-GmAb it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body. Using contrast agents with CT scan to enhance the images (contrast-enhanced CT) is standard of care imaging. 89Zr-DFO-GmAb PET/CT may be safe and effective compared to contrast-enhanced CT in detecting recurrent clear cell renal cell cancer after surgery.

NCT ID: NCT06447025 Enrolling by invitation - Friedreich Ataxia Clinical Trials

An Open Label Extension Study of CTI-1601 in Subjects With Friedreich's Ataxia

Jive
Start date: January 25, 2024
Phase: Phase 2
Study type: Interventional

This is an open-label extension (OLE) study designed to evaluate the long-term safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of subcutaneous (SC) administration of CTI-1601, also known as nomlabofusp, in subjects with Friedreich's ataxia (FRDA). The objectives of this OLE study are: - To evaluate the safety of long-term subcutaneous (SC) administration of CTI-1601 in subjects with FRDA - To evaluate the PK of long-term subcutaneous (SC) administration of CTI-1601 in subjects with FRDA - To evaluate the effect of long-term subcutaneous (SC) administration of CTI-1601 in subjects with FRDA on: - Tissue FXN concentrations - Clinical evaluations of FRDA - Gene Expression and select lipids

NCT ID: NCT06446765 Not yet recruiting - Clinical trials for Borderline Personality Disorder

Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder

MIND-BPD
Start date: February 2025
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the ability of mindfulness-based real time functional magnetic resonance imaging (fMRI) neurofeedback (mbNF) to increase the benefits of evidence-based psychotherapy for adults with Borderline Personality Disorder (BPD).